No Data
No Data
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $163 to $230
Top Gap Ups and Downs on Thursday: CIEN, WBD, ADBE and More
Morgan Stanley Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, $175 Price Target
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $163
Piper Sandler Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)